UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Multiplex genome engineering in Clostridium beijerinckii NCIMB 8052 using CRISPR-Cas12a

Scientific reports, 2023-06, Vol.13 (1), p.10153-10153, Article 10153

2023

Volltextzugriff (PDF)

Active Surveillance for Prostate Cancers Detected in Three Subsequent Rounds of a Screening Trial: Characteristics, PSA Doubling Times, and Outcome

European urology, 2007-05, Vol.51 (5), p.1244-1251

2007

Volltextzugriff (PDF)

Replacing the Calvin cycle with the reductive glycine pathway in Cupriavidus necator

Metabolic engineering, 2020-11, Vol.62, p.30-41

2020

Volltextzugriff (PDF)

Go/No-Go Training Changes Food Evaluation in Both Morbidly Obese and Normal-Weight Individuals

Journal of consulting and clinical psychology, 2018-12, Vol.86 (12), p.980-990

2018

Volltextzugriff (PDF)

Use of a Golden Gate Plasmid Set Enabling Scarless MoClo-Compatible Transcription Unit Assembly

Methods in molecular biology (Clifton, N.J.), 2025, Vol.2850, p.105

2025

Volltextzugriff (PDF)

Rnf2 (Ring1b) Deficiency Causes Gastrulation Arrest and Cell Cycle Inhibition

Proceedings of the National Academy of Sciences - PNAS, 2003-03, Vol.100 (5), p.2468-2473

2003

Volltextzugriff (PDF)

Prostate-specific antigen change in the european randomized study of screening for prostate cancer, section rotterdam

Urology (Ridgewood, N.J.), 2004-02, Vol.63 (2), p.316-320

2004

Volltextzugriff (PDF)

Overall and Disease-Specific Survival of Patients with Screen-Detected Prostate Cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam

European urology, 2007-02, Vol.51 (2), p.366-374

2007

Volltextzugriff (PDF)

hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4–10 ng/ml

European urology, 2007-11, Vol.52 (5), p.1358-1364

2007

Volltextzugriff (PDF)

Prevalence, Treatment Modalities and Prognosis of Familial Prostate Cancer in a Screened Population

The Journal of urology, 2006-04, Vol.175 (4), p.1332-1336

2006

Volltextzugriff (PDF)

Screening for prostate cancer without digital rectal examination and transrectal ultrasound: Results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam

The Prostate, 2006-05, Vol.66 (6), p.625-631

2006

Volltextzugriff (PDF)

Development of Renal Function After Neonatal Urinary Ascites Due to Obstructive Uropathy

The Journal of urology, 2002-08, Vol.168 (2), p.675-678

2002

Volltextzugriff (PDF)

3D-printed open-source sensor flow cells for microfluidic temperature, electrical conductivity, and pH value determination

Journal of flow chemistry, 2024, Vol.14 (2), p.469-479

2024

Volltextzugriff (PDF)

PROSTATE CANCER CHARACTERISTICS AND PROSTATE SPECIFIC ANTIGEN CHANGES IN SCREENING DETECTED PATIENTS INITIALLY TREATED WITH A WATCHFUL WAITING POLICY

The Journal of urology, 2004-12, Vol.172 (6), p.2193-2196

2004

Volltextzugriff (PDF)

Additional use of [−2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer

Urology (Ridgewood, N.J.), 2005-05, Vol.65 (5), p.926-930

2005

Volltextzugriff (PDF)

631: Watchful Waiting in the European Randomized Study of Screening for Prostate Cancer (Section Rotterdam) and Subsequent Therapy Change

The Journal of urology, 2004-04, Vol.171 (4), p.168-168

2004

Volltextzugriff (PDF)

621: Final Results of the Initial and Second Prostate Cancer Screening Round of the European Randomized Study of Screening for Prostate Cancer (ERSPC, Section Rotterdam)

The Journal of urology, 2004-04, Vol.171 (4), p.165-165

2004

Volltextzugriff (PDF)

623: Four Year Prostate Specific Antigen (PSA) Progression and Prostate Cancer Detection in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Section Rotterdam

The Journal of urology, 2004-04, Vol.171 (4), p.166-166

2004

Volltextzugriff (PDF)

1660: Propsa Improves Prostate Cancer Detection and Tumor Aggressiveness in PSA Range 2.0 - 3.9 NG/ML

The Journal of urology, 2004-04, Vol.171 (4), p.439-439

2004

Volltextzugriff (PDF)

Development of Renal Function After Neonatal Urinary Ascites Due to Obstructive Uropathy

The Journal of urology, 2002-08, p.675-678

2002

Volltextzugriff (PDF)

Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial : Characteristics, psa doubling times, and outcome. Commentary

European urology, 2007, Vol.51 (5), p.1244-1251

2007

Volltextzugriff (PDF)

The Role of Conservative Policies in the Treatment of Prostate Cancer

Challenges in Prostate Cancer, 2006, p.153-166

2006

Volltextzugriff (PDF)

Tumor-associated macrophages in breast cancer: Innocent bystander or important player?

Cancer treatment reviews, 2018-11, Vol.70, p.178-189

2018

Volltextzugriff (PDF)

New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective

The Lancet infectious diseases, 2016-12, Vol.16 (12), p.e288-e303

2016

Volltextzugriff (PDF)

Molecular Imaging in Cancer Drug Development

Journal of Nuclear Medicine, 2018-05, Vol.59 (5), p.726-732

2018

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Englisch
(93)
Niederländisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Multiplex genome engineering in Clostridium beijerinckii NCIMB 8052 using CRISPR-Cas12a

Active Surveillance for Prostate Cancers Detected in Three Subsequent Rounds of a Screening Trial: Characteristics, PSA Doubling Times, and Outcome

Replacing the Calvin cycle with the reductive glycine pathway in Cupriavidus necator

Go/No-Go Training Changes Food Evaluation in Both Morbidly Obese and Normal-Weight Individuals

Use of a Golden Gate Plasmid Set Enabling Scarless MoClo-Compatible Transcription Unit Assembly

Rnf2 (Ring1b) Deficiency Causes Gastrulation Arrest and Cell Cycle Inhibition

Prostate-specific antigen change in the european randomized study of screening for prostate cancer, section rotterdam

Overall and Disease-Specific Survival of Patients with Screen-Detected Prostate Cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam

hK2 and Free PSA, a Prognostic Combination in Predicting Minimal Prostate Cancer in Screen-Detected Men within the PSA Range 4–10 ng/ml

Prevalence, Treatment Modalities and Prognosis of Familial Prostate Cancer in a Screened Population

Screening for prostate cancer without digital rectal examination and transrectal ultrasound: Results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam

Development of Renal Function After Neonatal Urinary Ascites Due to Obstructive Uropathy

3D-printed open-source sensor flow cells for microfluidic temperature, electrical conductivity, and pH value determination

PROSTATE CANCER CHARACTERISTICS AND PROSTATE SPECIFIC ANTIGEN CHANGES IN SCREENING DETECTED PATIENTS INITIALLY TREATED WITH A WATCHFUL WAITING POLICY

Additional use of [−2] precursor prostate-specific antigen and “benign” PSA at diagnosis in screen-detected prostate cancer

631: Watchful Waiting in the European Randomized Study of Screening for Prostate Cancer (Section Rotterdam) and Subsequent Therapy Change

621: Final Results of the Initial and Second Prostate Cancer Screening Round of the European Randomized Study of Screening for Prostate Cancer (ERSPC, Section Rotterdam)

623: Four Year Prostate Specific Antigen (PSA) Progression and Prostate Cancer Detection in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Section Rotterdam

1660: Propsa Improves Prostate Cancer Detection and Tumor Aggressiveness in PSA Range 2.0 - 3.9 NG/ML

Development of Renal Function After Neonatal Urinary Ascites Due to Obstructive Uropathy

Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial : Characteristics, psa doubling times, and outcome. Commentary

The Role of Conservative Policies in the Treatment of Prostate Cancer

Tumor-associated macrophages in breast cancer: Innocent bystander or important player?

New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective

Molecular Imaging in Cancer Drug Development

Suchergebnisse filtern